Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14894559 | 0.87 | SLC6A4 (0.41) | EPHX2SLC6A4SLC6A3SLC6A2TRPV1 | |
| SCHEMBL14894428 | 0.86 | OPRL1 (0.45) | EPHX2SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL21820750 | 0.83 | SLC6A4 (0.50) | EPHX2SLC6A4SLC6A3SLC6A2PDE2A | |
| SCHEMBL21820719 | 0.78 | SLC6A4 (0.41) | EPHX2SLC6A4SLC6A3SLC6A2TRPV1 | |
| SCHEMBL20703425 | 0.78 | MEN1 (0.37) | SLC6A3RAB9A | |
| SCHEMBL15522936 | 0.77 | TLR7 (0.49) | POLBTRPV1PDE2ANPC1RAB9A | |
| SCHEMBL25431969 | 0.71 | MEN1 (0.44) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL14894469 | 0.71 | OPRM1 (0.45) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL1465617 | 0.71 | KMT2A (0.48) | EPHX2SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL14894684 | 0.71 | HDAC3 (0.40) | EPHX2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772499-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20140080803-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2014-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080803-A1 | NOVEL TRPV3 MODULATORS | TRPV3, TRPV4, TRPV5 | EPHX2 2335/4885SLC6A4 498/4885SLC6A3 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.